Curated News
By: NewsRamp Editorial Staff
May 16, 2025
NanoViricides, Inc. Announces Progress on Antiviral Drug NV-387 and Plans for Phase II Trials
TLDR
- NNVC advances with Phase II trial for MPox, targeting measles and avian flu, showing superior antiviral activity, necessitating additional funding.
- NanoViricides progresses NV-387 antiviral drug candidate, completing Phase I with no adverse events, aiming for broad-spectrum efficacy against various viruses.
- NanoViricides' NV-387 could revolutionize antiviral therapy, offering hope for more effective treatments against respiratory infections, making the world healthier.
- NV-387 demonstrates promising antiviral efficacy, potentially reshaping treatment approaches for various infections, paving the way for innovative therapeutic solutions.
Impact - Why it Matters
This news matters as NanoViricides' innovative antiviral drug candidate shows promising results in preclinical studies. The progress towards Phase II trials signifies a step closer to potentially effective treatments for various viral infections, including COVID-19 and its variants.
Summary
NanoViricides, Inc. (NYSE American: NNVC) announced progress on its antiviral drug candidate NV-387 and plans for Phase II trials targeting various viral infections. The company reported financial figures and highlighted the need for additional funding to support operations beyond early 2026.
The company's lead drug candidate, NV-387, showed superior activity in animal models compared to existing antivirals for COVID, influenza, RSV, and smallpox. NanoViricides is also advancing NV-387 into Phase II human clinical trials, with a focus on treating respiratory viral infections, including COVID-19 and Long COVID.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides, Inc. Announces Progress on Antiviral Drug NV-387 and Plans for Phase II Trials
